arrow
L

Lorna Hopcroft

AstraZeneca
H指数:7
被引数:304

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer

FOXO3与FOXM1的相互作用影响PIK3CA及PIK3CA/PTEN变异的雌激素受体阳性乳腺癌对AKT抑制的敏感性。

2025-04-220
OA
Metabolism-driven in vitro/in vivo disconnect of an oral ERα VHL-PROTAC
2024-05-135
OAAI
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
2023-09-190
OAAI
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models (vol 9, 64, 2023)
2023-08-180
OA
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
2023-08-0512
OAAI
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

发现临床候选药物AZD0095,一种用于肿瘤学的单羧酸转运蛋白4 (MCT4) 的选择性抑制剂

2022-12-1623
PRE